metformin longevity: one bounded, context-dependent signal across receipts

Source literature boundary memo

Research question

Across retrieved source-level receipts for metformin_longevity, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?

Selection criteria

The source-literature fallback selected metformin_longevity because the domain snapshot exposed enough source-backed, topic-overlapping papers. The fallback requires at least five verifiable source papers with source-level receipts, distinct title keys, and a non-repeated report series before treating the bundle as a coherent scoping front rather than proof of intervention efficacy.

Boundary map

• Association Between Preadmission Metformin Use and Outcomes in Intensive Care Unit Patients With Sepsis and Type 2 Diabetes: A Cohort Study [primary; 2021] doi:10.3389/fmed.2021.640785
  • Finding: preadmission metformin use was associated with 39% lower of 30-day mortality (HR = 0.61, 95% CI: 0.46-0.81, p = 0.007)
  • Population: sepsis patients with type 2 diabetes
  • Intervention/exposure: preadmission metformin use
  • Comparator: non-metformin use
• Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer [primary; 2020] doi:10.1172/jci.insight.133247
  • Finding: median progression-free survival was 18.0 months (95% CI 14.0-21.6)
  • Population: nondiabetic patients with advanced-stage epithelial ovarian cancer
  • Intervention/exposure: metformin with chemotherapy and debulking surgery
  • Comparator: historical controls
• The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis [review; 2020] doi:10.1016/j.dsx.2020.11.006
  • Finding: Metformin is associated with lower mortality in pooled non-adjusted model (OR 0.45 [0.25, 0.81], p = 0.008; I2: 63.9%, p = 0.026)
  • Population: hospitalized adult COVID-19 patients
  • Intervention/exposure: Metformin consumption
  • Comparator: non-metformin
• Use of metformin and survival of patients with high‐grade glioma [primary; 2018] doi:10.1002/ijc.31783
  • Finding: Use of metformin was associated with a significantly better overall and progression-free survival of patients with WHO grade III glioma (HR for OS = 0.30; 95% CI = 0.11-0.81)
  • Population: patients with WHO grade III glioma (high-grade glioma)
  • Intervention/exposure: use of metformin
  • Comparator: no metformin
• Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders [review; 2014] doi:10.1158/1940-6207.capr-13-0424
  • Finding: Overall cancer incidence was reduced by 31% [summary relative risk (SRR), 0.69; 95% confidence interval (CI), 0.52-0.90]
  • Population: patients with diabetes
  • Intervention/exposure: metformin
  • Comparator: control

Source synthesis

This receipt-backed scoping note has one bounded signal: metformin_longevity shows endpoint-specific favorable signals with context limits across this 5-source primary/review bundle (2014-2021). Grouped by direction: directionally favorable: 4 receipt(s) | other/mixed: 1 receipt(s). The source facts cover 5 population context(s) and 5 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim. Concrete source-level examples: preadmission metformin use was associated with 39% lower of 30-day mortality (HR = 0.61, 95% CI: 0.46-0.81, p = 0.007); median progression-free survival was 18.0 months (95% CI 14.0-21.6); Metformin is associated with lower mortality in pooled non-adjusted model (OR 0.45 [0.25, 0.81], p = 0.008; I2: 63.9%, p = 0.026).

Directional grouping

• directionally favorable: metformin_longevity is the intervention/exposure and the reported clinical endpoint favors that arm.

• comparator/not favorable: metformin_longevity is the comparator arm; the label is limited to that head-to-head endpoint.

• economic/context only: the receipt reports cost, QALY, or economic context rather than a clinical efficacy endpoint.

• non-clinical/predictive: the receipt reports descriptive modelling, prediction, or age-clock performance rather than an intervention endpoint.

• null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.

• directionally favorable: Association Between Preadmission Metformin Use and Outcomes in Intensive Care Unit Patients With Sepsis and Type 2 Diabetes: A Cohort Study — preadmission metformin use was associated with 39% lower of 30-day mortality (HR = 0.61, 95% CI: 0.46-0.81, p = 0.007)

• other/mixed: Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer — median progression-free survival was 18.0 months (95% CI 14.0-21.6)

• directionally favorable: The Effect of Metformin Consumption on Mortality in Hospitalized COVID-19 patients: a systematic review and meta-analysis — Metformin is associated with lower mortality in pooled non-adjusted model (OR 0.45 [0.25, 0.81], p = 0.008; I2: 63.9%, p = 0.026)

• directionally favorable: Use of metformin and survival of patients with high‐grade glioma — Use of metformin was associated with a significantly better overall and progression-free survival of patients with WHO grade III glioma (HR for OS = 0.30; 95% CI = 0.11-0.81)

• directionally favorable: Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders — Overall cancer incidence was reduced by 31% [summary relative risk (SRR), 0.69; 95% confidence interval (CI), 0.52-0.90]

Specific moderators in this bundle are population/indication (hospitalized adult COVID-19 patients; nondiabetic patients with advanced-stage epithelial ovarian cancer; patients with WHO grade III glioma (high-grade glioma); patients with diabetes; sepsis patients with type 2 diabetes), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable.

Context separation

The selected receipts group because each carries a fact-level extraction for metformin_longevity; they separate by context (human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim.

Boundary limits

Source-literature boundary for metformin_longevity: the listed sources define one bounded, context-dependent signal across separate source contexts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources. The signal is purely descriptive of effect-direction heterogeneity; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate. Routing domain longevity_research is publication-lane metadata only; the source scope here is defined by the selected metformin_longevity receipts.

Next gaps

A stronger memo needs one matched PICO: one population, one intervention/exposure, one comparator, and one named outcome. If metformin_longevity is promoted beyond a scoping note, the next run should select sources sharing one context family rather than mixing human clinical/observational.